JP2014524411A - インスリン分泌促進剤 - Google Patents

インスリン分泌促進剤 Download PDF

Info

Publication number
JP2014524411A
JP2014524411A JP2014523151A JP2014523151A JP2014524411A JP 2014524411 A JP2014524411 A JP 2014524411A JP 2014523151 A JP2014523151 A JP 2014523151A JP 2014523151 A JP2014523151 A JP 2014523151A JP 2014524411 A JP2014524411 A JP 2014524411A
Authority
JP
Japan
Prior art keywords
compound
alkyl
branched
cycloalkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014523151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524411A5 (enExample
Inventor
エス． アール． マーシー マディラジュ，
マルク プレントキ，
エリック ジョリー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier de lUniversite de Montreal CHUM
Original Assignee
Centre Hospitalier de lUniversite de Montreal CHUM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier de lUniversite de Montreal CHUM filed Critical Centre Hospitalier de lUniversite de Montreal CHUM
Publication of JP2014524411A publication Critical patent/JP2014524411A/ja
Publication of JP2014524411A5 publication Critical patent/JP2014524411A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2014523151A 2011-08-03 2012-07-31 インスリン分泌促進剤 Ceased JP2014524411A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161514563P 2011-08-03 2011-08-03
US61/514,563 2011-08-03
PCT/CA2012/000721 WO2013016807A1 (en) 2011-08-03 2012-07-31 Insulin secretion promoting agents

Publications (2)

Publication Number Publication Date
JP2014524411A true JP2014524411A (ja) 2014-09-22
JP2014524411A5 JP2014524411A5 (enExample) 2015-12-03

Family

ID=47628579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523151A Ceased JP2014524411A (ja) 2011-08-03 2012-07-31 インスリン分泌促進剤

Country Status (5)

Country Link
US (2) US9371285B2 (enExample)
EP (1) EP2739608B1 (enExample)
JP (1) JP2014524411A (enExample)
CA (1) CA2842450A1 (enExample)
WO (1) WO2013016807A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022211060A1 (enExample) * 2021-04-01 2022-10-06
JP2024052624A (ja) * 2022-09-30 2024-04-11 小野薬品工業株式会社 Ａｂｈｄ６アンタゴニストを含有する医薬組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015127559A1 (en) * 2014-02-28 2015-09-03 Val-Chum, Limited Partnership Abhd6 antagonists for promoting browning of white adipose tissue and brown adipose tissue functionality
CN112300122A (zh) * 2019-07-26 2021-02-02 南京理工大学 三氮唑类杂环化合物及其合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140659A1 (en) 2010-05-12 2011-11-17 Centre Hospitalier De L'universite De Montreal Screening assays based on mag and/or abhd6 for selecting insulin secretion promoting agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BACHOVCHIN, D. A. ET AL, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 107, no. 49, JPN6016005265, 2010, pages p.20941-20946, suppl. *
LI, W. ET AL, JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, JPN6016005264, 2007, pages vol.129, no.31 *
ZHAO, SHANGANG: "Monoacylglycerol as a metabolic coupling factor in glucose-stimulated insulin secretion", MEMOIRE PRESENTEE A LA FACULTE DES ETUDES SUPERIEURES EN VUE DE I'OBTENTION DU GRADE DE MAITRE ES SC, JPN6016047038, 2010, pages 全文 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022211060A1 (enExample) * 2021-04-01 2022-10-06
WO2022211060A1 (ja) * 2021-04-01 2022-10-06 小野薬品工業株式会社 Ａｂｈｄ６アンタゴニスト
CN117120435A (zh) * 2021-04-01 2023-11-24 小野药品工业株式会社 Abhd6拮抗剂
US11981682B2 (en) 2021-04-01 2024-05-14 Ono Pharmaceutical Co., Ltd. Substituted cyclopenta[c]pyrroles as ABHD6 antagonists
JP7525058B2 (ja) 2021-04-01 2024-07-30 小野薬品工業株式会社 Ａｂｈｄ６アンタゴニスト
JP2024128038A (ja) * 2021-04-01 2024-09-20 小野薬品工業株式会社 Ａｂｈｄ６アンタゴニスト
JP7750341B2 (ja) 2021-04-01 2025-10-07 小野薬品工業株式会社 Ａｂｈｄ６アンタゴニスト
JP2024052624A (ja) * 2022-09-30 2024-04-11 小野薬品工業株式会社 Ａｂｈｄ６アンタゴニストを含有する医薬組成物

Also Published As

Publication number Publication date
EP2739608A4 (en) 2014-12-17
EP2739608A1 (en) 2014-06-11
WO2013016807A1 (en) 2013-02-07
CA2842450A1 (en) 2013-02-07
US20140163077A1 (en) 2014-06-12
US9371285B2 (en) 2016-06-21
US20160264527A1 (en) 2016-09-15
US9518016B2 (en) 2016-12-13
EP2739608B1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
US5326770A (en) Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US20250382309A1 (en) Methods and materials for increasing transcription factor eb polypeptide levels
CN113831301A (zh) 苯并噻唑类衍生物及其用途
CA2974726C (en) Imidazolyl tricyclic enones as antioxidant inflammation modulators
US9518016B2 (en) Insulin secretion promoting agents
FR2871463A1 (fr) Derives a structure aroyl-o-piperidine, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en therapeutique
JP2019504016A (ja) アルキルジヒドロキノリンスルホンアミド化合物
JP7665122B2 (ja) ハロアリルアミン系二重アミンオキシダーゼ阻害剤
JP7644991B2 (ja) シスチン尿症のためのシスチンジアミド類似体
CN103319402A (zh) 二苯基硫脲类衍生物及其制备方法和应用
EP0741697A1 (en) Amino acid derivatives and their use as phospholipase a2 inhibitors
US10519105B2 (en) KCNQ2-5 channel activator
JP4550353B2 (ja) 造血器型プロスタグランジンｄ２合成酵素阻害剤
US20200055868A1 (en) Pyridine derivative
CN119278197A (zh) 作为钾通道抑制剂的咪唑衍生物
KR20070114197A (ko) 씨피티를 억제하는 아미노부탄산의 유도체
EP4206184A1 (en) Phenol derivative
CN109422751A (zh) 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
CA2938520A1 (en) Abhd6 antagonists for promoting browning of white adipose tissue and brown adipose tissue functionality
CN111372928B (zh) 用作钾通道抑制剂的苯并咪唑衍生物
US20240285777A1 (en) Inhibitors of ttbk1
ES2588597T3 (es) Compuestos que presentan actividad antibacteriana, procedimientos utilizables en su preparación y composiciones farmacéuticas que los comprenden
KR101803955B1 (ko) 신규한 메틸시클로헥산 유도체 및 그의 용도
EP2185525B1 (fr) Dérivés de pyrazole 3,5-carboxylates, leur préparation et leur application en thérapeutique
JP2020186182A (ja) 標的蛋白質分解誘導化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140624

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150904

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170530

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170802

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20171222